Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 208 results for myocardial infarction

  1. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA394

  2. Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis (HTG704)

    Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.

    HealthTech guidance
    Published
    22 November 2023
    View recommendations

    Sections for HTG704

  3. Intra-aortic balloon counter‑pulsation: In people with acute heart failure and hypoperfusion syndrome, is the use of intra‑aortic balloon counter‑pulsation pump (IABP) better than the use of intravenous inotropes?

    complications of acute myocardial infarction. It has also been used in people who develop cardiogenic shock after acute myocardial...

    Research recommendation
    Published
    16 December 2021

  4. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

    HealthTech guidance
    Published
    23 February 2011
    View recommendations

    Sections for HTG251

  5. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494

  6. Endovascular stent insertion for intracranial atherosclerotic disease (HTG288)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

    HealthTech guidance
    Published
    23 July 2012
    View recommendations

    Sections for HTG288

  7. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

    HealthTech guidance
    Published
    24 March 2010
    View recommendations

    Sections for HTG213

  8. Chronic kidney disease in adults (QS5)

    This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    27 July 2017
    View quality statements

    Sections for QS5

  9. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    6 October 2021
    View recommendations

    Sections for TA733

  10. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    18 February 2026

    Sections for NG28

  11. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

    Medtech innovation briefing
    Published
    8 May 2019

  12. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  13. Disease-specific reference case extension: management of overweight and obesity in adults (PMG50)

    This NICE disease-specific reference case extension describes standardised methods for health economic evaluations of interventions for managing overweight and obesity in adults. For further details on developing and implementing disease-specific reference case extensions, see NICE’s position statement on use of disease-specific reference models in economic evaluations

  14. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA278

  15. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

    Medtech innovation briefing
    Published
    18 January 2017